Sividon Diagnostics | GenomeWeb

Sividon Diagnostics

The acquisition provides Myriad with the EndoPredict test, which is currently offered in Europe and is expected to launch in the US next year.

The analysis showed that one out of 227 node-negative breast cancer patients with the lowest EPclin scores by Sividon's EndoPredict test experienced recurrence over 10 years.

At the San Antonio Breast Cancer Symposium, a Sividon collaborator is scheduled to present a new study including a comparison between EndoPredict and Oncotype DX.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.